Tandem Diabetes Care, Inc. Aktie News

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results after the financial markets close on Thursday, November 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third qua...

LOS ANGELES, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company's possible violations of the federal securities laws.

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) on behalf of investors concerning the Company's possible violations of federal securities laws.

SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--t:slim X2 insulin pump with Control-IQ+ technology now cleared for use with Lyumjev ultra-rapid acting insulin in the U.S.

NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.